Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 20403398)

  • 1. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
    Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
    J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
    Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
    J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
    Withey JM; Harvey AJ; Crompton MR
    Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
    Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
    Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
    Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
    Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of eukaryotic expression vector of siRNA specific to bcr/abl fusion gene].
    Xi YM; Liu T; Meng WT; Wang YH; Gu L; Lu XX; Gong YP
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):460-3. PubMed ID: 16078560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
    Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
    J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
    Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
    J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression.
    Baker BE; Kestler DP; Ichiki AT
    J Biomed Sci; 2006 Jul; 13(4):499-507. PubMed ID: 16547768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
    Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
    Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
    Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
    Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
    Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
    Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
    Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
    Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.